CEO & Co-Founder, Bexson Biomedical
Bexson Biomedical is developing subcutaneous formulation technology and a wearable device for several psychedelic compounds. Gregg has over 20 years of experience developing pharmaceutical, medical device, biologic and combination products, leading to launch of 12 products globally. He was previously a Global R&D Program Lead for S&P500 company with a focus on US, EU and AsiaPac. He has a successful history directing R&D programs from market need analysis and ideation, through Phase III clinical trials, and to regulatory approval. Gregg is a veteran of multiple startup companies including Evolus (IPO), TargeGen (sale to Sanofi-Aventis) and Somaxon (IPO). He holds a B.S. from University of Puget Sound and a M.A. from the Medical College of Wisconsin.